This morning, the group of Industries Bio technological and Pharmaceutical Biocubafarma, announced that it has been created the first enterprise of bio technology Cuban-U.S Innovative Immunotherapy Alliance SA, which will have its headquarters in the special zone of Development Mariel.
This new mixed enterprise has been created among the trade branches of two renowned investigation centers: the center of Molecular Immunology of Cuba and the Roswell Park Comprehensive Cancer Center of the U.S.
This historical step in the scientific collaboration between both countries will allow the advance of the investigation and the development of new medications against cancer, which could prolong and improve the survival of thousands of patients in the U.S.
The new biotechnological enterprise will count on among their products with the medication CIMAVax-EGF, renowned therapy against lung cancer, and other three additional treatments of immunotherapy for different tumors, developed in Cuba.
In the first years, the enterprise will have as a main objective to develop the scientific and clinic investigation allowing to show the security and effectiveness of these new treatments in the U.S. If resulting successful these studies, the enterprise will be in conditions to export these products for the benefit of American patients, once obtained the necessary approvals by the regulator agency of medications of this country.